following an abbreviated submission:
budesonide/formoterol (Symbicort® SMART®) is accepted for use within NHS Scotland.
Indication under review: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
This advice relates to the extension of the license for Symbicort maintenance and reliever therapy (SMART®) to adolescents aged 12 to <18 years.
SMC has previously accepted Symbicort maintenance and reliever therapy (SMART®) in adults.
Download detailed advice128KB (PDF)
Medicine details
- Medicine name:
- budesonide-formoterol (Symbicort SMART)
- SMC ID:
- 1244/17
- Indication:
- the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 June 2017